Given the absence of an effective vaccine for protection against HIV-1 infection, passive
immunization strategies that utilize potent broadly neutralizing antibodies (bnAbs) to block …

Passive immunization with broadly neutralizing antibodies (bnAbs) is a promising approach
to reduce the 1.7 million annual human immunodeficiency virus (HIV) infections globally …

Antibodies that naturally develop in some individuals infected with human immunodeficiency
virus 1 (HIV-1) and are capable of broadly neutralizing diverse strains of HIV-1 are useful for …

Encouraging results from preclinical and clinical studies support the development of bNAbs
for prevention and a number of antibodies with exceptional breadth and potency are …

Despite immense progress in our ability to prevent and treat HIV-1 infection, HIV-1 remains
an incurable disease and a highly efficacious HIV-1 vaccine is not yet available. Additional …

Many broadly neutralizing antibodies (bnAbs) targeting the HIV-1 envelope glycoprotein are
being assessed in clinical trials as strategies for HIV-1 prevention, treatment, and …

Introduction The last 12 years have seen remarkable progress in the isolation and
characterization of at least five different epitope classes of HIV‐specific broadly neutralizing …

Highlights•Broadly neutralizing antibodies are promising for HIV-1 prevention and
therapy.•Newly identified bNAbs reveal novel epitopes and binding modes.•Effective …

Combination antiretroviral therapy (cART) is effective but not curative, and no successful
vaccine is currently available for human immunodeficiency virus-1 (HIV-1). Broadly …

An increasing number of broadly neutralizing antibodies (bnAbs) are considered leads for
HIV-1 vaccine development and novel therapeutics. Here, we systematically explored the …